SouzanSanatiMD

Pathology • West Hollywood, CA

Cytopathology, Anatomic Pathology, Clinical Pathology, Surgical Pathology

Assistant Professor, Pathology & Immunology, Washington University School of Medicine

Join to view full profile

Dr. Sanati is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sanati's full profile

Already have an account?

Office
8700 Beverly Blvd
# SB290
West Hollywood, CA 90048
Phone+1 310-248-6240

Fax+1 310-439-1906

Education & Training

Yale-New Haven Medical CenterFellowship, Gynecologic Pathology, 2008 - 2009
Washington University/B-JH/SLCH ConsortiumFellowship, Cytopathology, 2006 - 2007
Washington University/B-JH/SLCH ConsortiumFellowship, Selective Pathology, 2005 - 2006
University of Texas Medical Branch HospitalsResidency, Pathology-Anatomic and Clinical, 2001 - 2005
Iran University of Medical SciencesClass of 1993

Certifications & Licensure

CA State Medical License 2015 - 2025
IL State Medical License 2016 - 2020
MO State Medical License 2007 - 2020
American Board of Pathology Pathology - Anatomic/Pathology - Clinical
American Board of Pathology Cytopathology

Clinical Trials

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Start of enrollment: 2013 Apr 10
Active, not recruiting
Phase 2
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer Start of enrollment: 2014 Aug 01
Withdrawn
Phase 2
Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer Start of enrollment: 2014 Apr 02
Completed
Not Applicable
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Start of enrollment: 2014 Jul 07
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

4 citations
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or...
Cynthia X Ma, Vera J Suman, Souzan Sanati, Kiran Vij, Meenakshi Anurag
JAMA Oncology. 2024-03-01
19 citations
Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association w...
Mieke R Van Bockstal, Aline François, Serdar Altinay, Laurent Arnould, Maschenka Balkenhol
Modern Pathology. 2021-07-03
8 citations
Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography
Quing Zhu, Foluso O. Ademuyiwa, Catherine A. Young, Catherine M. Appleton, Matthew F. Covington
Breast Cancer Research and Treatment. 2021-05-10

Journal Articles

Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer Xenografts
Souzan Sanati, Jana W Qiao, Xian Chen, Matthew J Ellis, Cynthia Ma, Nature